Transfusion-related Cost Offsets and Time Burden in Patients with Myelofibrosis on Momelotinib Vs. Danazol from MOMENTUM

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jul 29

PMID 39072442

Authors

Lucia Masarova

Srdan Verstovsek

Tom Liu

Sumati Rao

Gautam Sajeev

Mirko Fillbrunn

Ryan Simpson

Weilong Li

Joseph Yang

Yvette Le Lorier

Boris Gorsh

James Signorovitch

Affiliations

Soon will be listed here.

Abstract

To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.

Citing Articles

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.

Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M Ann Hematol. 2025; 104(1):241-251.

PMID: 39831987 PMC: 11868333. DOI: 10.1007/s00277-025-06204-5.

Masarova L, Liu T, Fillbrunn M, Li W, Sajeev G, Rao S Cancers (Basel). 2024; 16(23).

PMID: 39682253 PMC: 11640613. DOI: 10.3390/cancers16234067.

References

Pardanani A, Tefferi A . Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. Haematologica. 2011; 96(1):8-10. PMC: 3012757. DOI: 10.3324/haematol.2010.035519. View

Bartoszko J, Panzarella T, Lau A, Schimmer A, Schuh A, Shanavas M . Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2015; 15(11):e151-6. DOI: 10.1016/j.clml.2015.09.001. View

Harrison C, Vannucchi A, Platzbecker U, Cervantes F, Gupta V, Lavie D . Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017; 5(2):e73-e81. DOI: 10.1016/S2352-3026(17)30237-5. View

Gerds A, Tkacz J, Moore-Schiltz L, Schinkel J, Phiri K, Liu T . Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data. J Manag Care Spec Pharm. 2024; 30(12):1395-1404. PMC: 11607217. DOI: 10.18553/jmcp.2024.24050. View

Passamonti F, Harrison C, Mesa R, Kiladjian J, Vannucchi A, Verstovsek S . Anemia in myelofibrosis: Current and emerging treatment options. Crit Rev Oncol Hematol. 2022; 180:103862. DOI: 10.1016/j.critrevonc.2022.103862. View

Maffioli M, Mora B, Ball S, Iurlo A, Elli E, Finazzi M . A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022; 6(6):1855-1864. PMC: 8941454. DOI: 10.1182/bloodadvances.2021006889. View

Gupta V, Harrison C, Hexner E, Al-Ali H, Foltz L, Montgomery M . The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016; 101(12):e482-e484. PMC: 5479619. DOI: 10.3324/haematol.2016.151449. View

Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B . Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2021; 6(2):373-375. PMC: 8791590. DOI: 10.1182/bloodadvances.2021006006. View

Titmarsh G, Duncombe A, McMullin M, ORorke M, Mesa R, De Vocht F . How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014; 89(6):581-7. DOI: 10.1002/ajh.23690. View

10.

Mohammed A, Ntambwe P, Crawford A . Barriers to Effective Transfusion Practices in Limited-Resource Settings: From Infrastructure to Cultural Beliefs. World J Surg. 2020; 44(7):2094-2099. PMC: 7266790. DOI: 10.1007/s00268-020-05461-x. View

11.

Ganz T . Systemic iron homeostasis. Physiol Rev. 2013; 93(4):1721-41. DOI: 10.1152/physrev.00008.2013. View

12.

Pardanani A, Harrison C, Cortes J, Cervantes F, Mesa R, Milligan D . Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015; 1(5):643-51. DOI: 10.1001/jamaoncol.2015.1590. View

13.

Harrison C, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M . The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017; 96(10):1653-1665. PMC: 5569657. DOI: 10.1007/s00277-017-3082-y. View

14.

Raykar N, Makin J, Khajanchi M, Olayo B, Munoz Valencia A, Roy N . Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions. SAGE Open Med. 2021; 9:20503121211054995. PMC: 8591638. DOI: 10.1177/20503121211054995. View

15.

Scherber R, Mesa R . Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):118-126. PMC: 6245993. DOI: 10.1182/asheducation-2018.1.118. View

16.

Copher R, Kee A, Gerds A . Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States. Oncologist. 2022; 27(3):228-235. PMC: 8914486. DOI: 10.1093/oncolo/oyab058. View

17.

Tefferi A, Lasho T, Jimma T, Finke C, Gangat N, Vaidya R . One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012; 87(1):25-33. PMC: 3538387. DOI: 10.1016/j.mayocp.2011.11.001. View

18.

McLornan D, Saunders C, Harrison C . Considerations to comprehensive care for the older individual with myelofibrosis. Best Pract Res Clin Haematol. 2022; 35(2):101371. DOI: 10.1016/j.beha.2022.101371. View

19.

Tefferi A, Siragusa S, Hussein K, Schwager S, Hanson C, Pardanani A . Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2009; 85(1):14-7. DOI: 10.1002/ajh.21574. View

20.

Vannucchi A, Barbui T, Cervantes F, Harrison C, Kiladjian J, Kroger N . Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v85-99. DOI: 10.1093/annonc/mdv203. View